Dr. Steven J. Chmura is an Associate Professor in the Department of Radiation and Cellular Oncology and Director of Clinical and Translational Research at The University of Chicago.
Steven J. Chmura MD, PhD is the director of Clinical and Translational Research for Radiation Oncology at the University of Chicago for over a decade. He has been actively involved in both the clinical implementation of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) and related translational and clinical research, as well as the integration of SRS and SBRT into other systemic therapies. His clinical interests include breast cancer, limited metastatic disease, immunotherapy, and technologic improvements in the delivery of radiotherapy. Dr. Chmura is a leader in the NCI cooperative groups. His work has led to the first international oligmetastatic trials through NRG Oncology examining the safety of treating lung and breast cancer patients as a Phase II/III trial examining potential improvements to progression-free survival and overall survival. Dr. Chmura's work in radio-immunology has also translated into multiple investigator-sponsored trials along with the now accruing NCI-sponsored (A091605) trial randomizing the role of SBRT combined with pembrolizumab in advanced Merkel cell carcinoma; such integration of ablative radiotherapy and immunotherapy along with advancing the search for biomarkers is currently Dr. Chmura's focus.
University of Chicago
Chicago
- Radiation Oncology Board Certification
2005
University of Chicago
Chicago
PhD - Pathology
1999
University of Chicago
Chicago
MD - Medicine
1999
University of Illinois
Urbana
BS - Biology and Psychology
1992
Radiotherapy Enhances Metastasis Through Immune Suppression by inducing PD-L1 and MDSC in distal sites.
Radiotherapy Enhances Metastasis Through Immune Suppression by inducing PD-L1 and MDSC in distal sites. Clin Cancer Res. 2024 Mar 01.
PMID: 38427437
A multi-institutional phase I study of acetazolamide with temozolomide in adults with newly diagnosed MGMT-methylated malignant glioma.
A multi-institutional phase I study of acetazolamide with temozolomide in adults with newly diagnosed MGMT-methylated malignant glioma. Neurooncol Adv. 2024 Jan-Dec; 6(1):vdae014.
PMID: 38420615
Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials.
Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials. Int J Radiat Oncol Biol Phys. 2024 Apr 01; 118(5):1519-1530.
PMID: 38199382
Epitranscriptional regulation of TGF-ß pseudoreceptor BAMBI by m6A/YTHDF2 drives extrinsic radioresistance.
Epitranscriptional regulation of TGF-ß pseudoreceptor BAMBI by m6A/YTHDF2 drives extrinsic radioresistance. J Clin Invest. 2023 Dec 15; 133(24).
PMID: 38099498
Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations.
Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations. J Natl Cancer Inst. 2023 11 08; 115(11):1278-1293.
PMID: 37348864
De Novo Oligometastatic Breast Cancer.
De Novo Oligometastatic Breast Cancer. J Clin Oncol. 2023 Dec 01; 41(34):5237-5241.
PMID: 37607325
Should We Target Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy?
Should We Target Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy? J Natl Cancer Inst. 2023 06 08; 115(6):605-607.
PMID: 35094086
YTHDF2 inhibition potentiates radiotherapy antitumor efficacy.
YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023 07 10; 41(7):1294-1308.e8.
PMID: 37236197
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases.
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023 05 15; 133(10).
PMID: 37183819
Intracranial and Extracranial Progression and Their Correlation With Overall Survival After Stereotactic Radiosurgery in a Multi-institutional Cohort With Brain Metastases.
Intracranial and Extracranial Progression and Their Correlation With Overall Survival After Stereotactic Radiosurgery in a Multi-institutional Cohort With Brain Metastases. JAMA Netw Open. 2023 04 03; 6(4):e2310117.
PMID: 37099292